Polymorphisms and pharmacogenomics for the toxicity of methotrexate monotherapy in patients with rheumatoid arthritis: A systematic review and meta-analysis

BACKGROUND: Methotrexate (MTX) is widely used and considered a first-line disease modifying antirheumatic drug (DMARD) for the treatment of rheumatoid arthritis (RA). However, 10% to 30% of patients discontinue therapy within a year of starting the treatment, usually because of undesirable side effe...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiu, Qi, Huang, Jing, Lin, Yang, Shu, Xiaoming, Fan, Huizheng, Tu, Zhihua, Zhou, Youwen, Xiao, Cheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4400
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369916/
https://www.ncbi.nlm.nih.gov/pubmed/28296761
http://dx.doi.org/10.1097/MD.0000000000006337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369916/
https://www.ncbi.nlm.nih.gov/pubmed/28296761
http://dx.doi.org/10.1097/MD.0000000000006337

Ejemplares similares